Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Liposarcoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 46 Breast Neoplasms 39 Triple Negative Breast Neoplasms 19 Prostatic Neoplasms 18 Neoplasms 13 Fallopian Tube Neoplasms 13 Endometrial Neoplasms 12 Pancreatic Neoplasms 9 Recurrence 8 Neoplasm Metastasis 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Lung Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Glioma 5 Glioblastoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Carcinoma, Squamous Cell 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Stomach Neoplasms 3 Solid Tumor 3 Melanoma 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2

Interventions

Radiotherapy 8 Doxorubicin 7 pazopanib 5 palbociclib 4 Trabectedin 4 Gemcitabine 4 ribociclib 3 pembrolizumab 3 eribulin 3 selinexor 2 liposomal doxorubicin 2 avelumab 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Immunoglobulin G 2 Ifosfamide 2 Docetaxel 2 Cyclophosphamide 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 sotigalimab 1 sodium thiosulfate 1 sitravatinib 1 silmitasertib 1 sargramostim 1 romidepsin 1 regorafenib 1 plitidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡